Interview with Erik Lommerde, General Manager, Novo Nordisk BV
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Contact
Novo Nordisk B.V.
Flemingweg 18, 2408 AV Alphen aan den Rijn
Netherlands
T: +31-172 44 94 94
Web: http://ww.novonordisk.nl/
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What…
When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong…
WFIA is quite a remarkable organisation that has been, since its inception ten years ago, reporting very good results. The annual results last week showed another strong focus on the…
The Netherlands is famous throughout Europe and the global pharmaceutical community for its research infrastructure – institutes, university hospitals, and public private partnerships. Given this foundation and the size of…
Given the peculiarities of the pharmaceutical industry in the Netherlands, such as the highest generics penetration rate in Europe, a relatively small manufacturing presence and a considerably regulated market, what…
2010 was a very important year for Ferring as it marks the 60th anniversary of the company’s founding. Amongst the various commemorations this year and in hearing the collective experiences…
The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was…
“Two traditions one vision” was the phrase used to describe the 2005 merger that formed Daiichi Sankyo as it is today. While referring specifically to a corporate merger, its message…
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
See our Cookie Privacy Policy Here
